Shareholders
Serca Pharmaceuticals four main shareholders are:
The rest of the shares are distributed between several private investors, founders and management.
Soft funding
Serca Pharmaceuticals has been granted two projects by the Norwegian Research Council (NRC). The first project from 2019 – 2020 finished successfully and had subsidy framework of NOK 5 million. The second project started October 2020 and was finished June 2025. The total budget for the project was kr 33 million and NRC contributed with NOK 16 million. A third project started January 2025 and will continue into 2027. NRC has also contributed NOK 16 million to this new project.
Serca Pharmaceuticals is also part of SkatteFUNN.
